Abstract: The invention is a method for reducing the viral and microbial content of biological extracts which contain solids. The method comprises the steps of, (1), providing a biological extract which contains solids that comprise a biologically active substance, selected from enzymes, proteins and peptides, or a mixture of such substances; and (2) subjecting the biological extract to a high-pressure treatment; wherein the biological activity of the biological extract after the high-pressure treatment is at least 50% of the biological activity of the biological extract before the high-pressure treatment.

Abstract: In order to prevent impairment of the pharmacological effect of pancreatine through added auxiliary substances or binding agents a pancreatine pellet consists exclusively of pancreatine.

Abstract: In order to avoid compromising the pharmacological effect of pancreatin caused by the addition of auxiliary materials or binding agents, a pancreatin pellet having a 100% pancreatin content consists exclusively of pancreatin with a residual moisture content of less than 3% by weight, preferably less than 1% by weight or less than 0.5% by weight.

Abstract: The invention relates to a method for producing pancreatin with reduced viral and microbial contamination, comprising the steps of (a) providing the pancreatin in solid form with a residual moisture of 0.5 weight % or less, down to almost zero, based on the pancreatin provided; (b) subjecting the pancreatin provided in step (a) to a heat treatment at a temperature of 84° C., preferably 80° C. and below; wherein, the biological activity of the pancreatin obtained in step (b) corresponds to at least 50% of the biological activity of the pancreatin provided in step (a); and the viral infectiousness of the pancreatin obtained in step (b) has been reduced by a factor of more than 1 log10 in comparison with the viral infectiousness of the pancreatin provided in step (a), as well as a pancreatin produced according to this method and its use for producing a medicine or a nutritional supplement.

Abstract: In order to avoid compromising the pharmacological effect of pancreatin caused by the addition of auxiliary materials or binding agents, a pancreatin pellet having a 100% pancreatin content consists exclusively of pancreatin with a residual moisture content of less than 3% by weight, preferably less than 1% by weight or less than 0.5% by weight.

Abstract: The invention relates to a method for reducing the viral and microbial content of biological extracts which contain solids. It is provided that the method comprises the steps (a) provision of the biological extract which contains solids, comprising a biologically active substance, selected from enzymes, proteins and peptides, or a mixture of such substances; and (b) subjecting the biological extract provided in step (a) to a high-pressure treatment; wherein the biological activity of the biological extract which contains solids after the high-pressure treatment is at least 50% of the biological activity of the biological extract which contains solids before the high-pressure treatment.

Abstract: In order to prevent impairment of the pharmacological effect of pancreatine through added auxiliary substances or binding agents a pancreatine pellet consists exclusively of pancreatine.

Abstract: The invention relates to a method for reducing the virus and micro-organism content of biological extracts which contain solids. It is provided that the method comprises the steps (a) provision of a biological extract which contains solids in the form of a suspension, which consists of a liquid phase and solid particles dispersed therein, wherein the extract in step (a) comprises a mixture of enzymes, proteins and peptides, some of which is dissolved in the liquid phase and some of which can be bound to the solid particles or is present in pulverulent, solid form; and (b) irradiation of the biological extract provided in step (a); wherein the radiation used for the irradiation is selected from the group comprising ultra-violet radiation, x-ray radiation, ? radiation and ? radiation; and the enzymic activity of the biological extract which contains solids after irradiation is at least 50% of the enzymic activity of the biological extract which contains solids before irradiation.

Abstract: The invention relates to a method for producing pancreatin with reduced viral and microbial contamination, comprising the steps of (a) providing the pancreatin in solid form with a residual moisture of 0.5 weight % or less, down to almost zero, based on the pancreatin provided; (b) subjecting the pancreatin provided in step (a) to a heat treatment at a temperature of 84° C., preferably 80° C. and below; wherein, the biological activity of the pancreatin obtained in step (b) corresponds to at least 50% of the biological activity of the pancreatin provided in step (a); and the viral infectiousness of the pancreatin obtained in step (b) has been reduced by a factor of more than 1 log10 in comparison with the viral infectiousness of the pancreatin provided in step (a), as well as a pancreatin produced according to this method and its use for producing a medicine or a nutritional supplement.

Abstract: A dosing spoon for microtablets is described for which the lower part (1) of the spoon consists of an even polygone which possesses a border (2) on all sides with exception of one side and whereby the polygone has a number of individual recesses (3) which are formed in such a way that an individual microtablet fits in each individual recess.

Abstract: In order to provide solid, accurately dosable pharmaceutical presentations for individual dispensing from dosing devices which are, on the one hand, stable and uniformly and evenly dosable, and which, on the other hand, permit an accurate optimal individual dosage for the most different requirements by means of an accurate divisibility at will, it is proposed that the presentations constitute small spheroidal solid bodies comprising at least one active ingredient and, when needed, also pharmaceutical inactive ingredients and which have an accurate mass and active ingredient content.

Abstract: A process for producing pellets which are markedly spherical and have a particle size in the range from 0.1 to 4 mm and an apparent density above 0.5 g/cm.sup.3, and which are composed of 90-100% by weight of an ephedrine derivative and 0-10% by weight of a pharmaceutical aid, entails suspending ephedrine derivative powder with an average particle size of from 0.5 to 50 .mu.m at 0.degree.-90.degree. C. with stirring in a water-immiscible non solvent with a boiling point in the range from 60.degree. to 160.degree. C., adding 5-60% by weight, based on the ephedrine derivative, of an agglomerating liquid while continuing stirring, and, if there has been previous heating, cooling to from -5 to 25.degree. C. at 5-40K per hour, with the stirring speed being adjusted after the agglomeration of the powder particles to a value which is necessary for the required average particle size, and removing and drying the resulting pellets.

Abstract: A solid drug form containing not less than 90% by weight verapamil is produced by granulating at from 30.degree. to 55.degree. C. with a little water, drying and, where appropriate, conventional tableting or by pelleting, in which case the granules obtained as described are, after cooling, moistened once again and compacted in a granulating mixer at from 30.degree. to 55.degree. C. and are dried.

Abstract: A biconvex tablet whose height and diameter are approximately equal and are from 1.5 to 4 mm and which, besides conventional pharmaceutical auxiliaries, contains an antacid as active substance is described.

Abstract: A solid pharmaceutical sustained-release form, consisting of a core containing the active compound as well as conventional pharmaceutical auxiliaries, a coat which delays the release of the active compound and an antiadhesive outer layer, wherein the coat consists of a physiologically acceptable fat-like or wax-like hydrophobic layer which melts in the range from 30.degree. to 120.degree. C. and contains, in addition to conventional pharmaceutical auxiliaries, one or more water-insoluble polymers, and a process for its preparation.

Abstract: A process for the manufacture of pellets which are composed of xanthine derivatives and are predominantly spherical, have a particle size in the range of 0.3 to 4 mm and have a bulk density above 0.5 g/cm.sup.3 by reacting the appropriate xanthine derivative with water or a water/alcohol mixture, entails anhydrous powdered xanthine derivative with an average particle size of from 20 to 200 .mu.m being suspended by stirring at from 40.degree. to 70.degree. C. in a nonsolvent which is immiscible with water and has a boiling point in the range from 60.degree. to 160.degree. C., then adding from 10 to 40% by weight, based on the anhydrous xanthine derivative, of water or a water/alcohol mixture and subsequently allowing to cool to room temperature at from 5.degree. to 20.degree. C.

Abstract: Cylindrical microtablets which have a convex upper face and a convex lower face and whose cylinder diameter and height independently of one another are each from 1.0 to 2.5 mm and the ratio of the said diameter to said height is from 1:0.5 to 1:1.5, an a process for their preparation.

Abstract: In an apparatus for removing portions of identical materials (4) in the form of pieces by means of a sliding part which is encased in a dispensing container and operated from the outside and whose dispensing sector (5) is filled from inside the container and can be emptied outward, the sliding part is in the form of a tube section (1) which has one or more dispensing sectors (5) and is fed through an outer shell (3) and a stripper (2) located adjacent to the ejection orifice (9) and assigned to the dispensing sectors (5).

Abstract: Cylindrical microtablets which have a convex upper face and a convex lower face and whose cylinder diameter and height independently of one another are each from 1.0 to 2.5 mm and the ratio of the said diameter to said height is from 1:0.5 to 1:1.5, and a process for their preparation.

Abstract: A process for the preparation of solid pharmaceutical products, wherein, in a first step, spherical single crystals of a pharmaceutical active compound or assistant are prepared by agitating a saturated aqueous, organic or organic-aqueous solution in high speed stirred crystallizers or draft-tube crystallizers at 50-500 revolutions per minute and seeding the solution with finely ground seed crystals of particle size less than 100 .mu.m, while ensuring that at the time of addition of the seed crystals and during the growth thereof the solution is at all times only minimally supersaturated, this being achieved by slow cooling at a rate of not more than 50 K/h or corresponding slow evaporation of the solution, and in a second step the resulting spherical single crystals with diameters of 0.1-3 mm, preferably 0.5-2 mm, are separated from the solution, dried at 40.degree.-200.degree. C.